Another win for CogState

By Dylan Bushell-Embling
Tuesday, 12 August, 2008

CogState [ASX: CGS] has signed a contract worth $1.2 million which will see the company provide technology to a major pharmaceutical company for use in a Phase III schizophrenia study.

The cognition specialist company will be providing its computerised cognitive testing technology for the trial, which is to be conducted in over 70 sites.

This is the ninth contract the company has signed since July.

The nine contracts have a combined value of $2.3 million, and CogState is expecting that 63 per cent of the contracts' revenue will be earned in the coming financial year.

Related News

Novel antibiotic activates 'suicide' mechanism in superbug

Researchers have discovered a new class of antibiotic that selectively targets Neisseria...

Modifications in the placenta linked to psychiatric disorders

Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...

ADHD may be linked with an increased risk of dementia

An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd